ScreenerHero

SPRBSpruce Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · sprucebio.com
51.58USD-0.78%Mkt Cap: 148.24M $P/E: —

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap148.24M $
Enterprise Value60.78M $
Revenue (TTM)—
Gross Profit-22.95M $
Net Income (TTM)-38.97M $
Revenue/Share—
Last Price51.58 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)6.42
PEG—
EV/EBITDA-1.56
EV/Revenue—
P/S—
P/B2.06
EPS (TTM)-37.93
EPS (Forward)8.09
52W Range
7.00019% of range240.00
52W High240.00 USD
52W Low7.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-91.65%
ROA-73.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.33M $
CapEx (TTM)—
FCF Margin—
FCF Yield-13.93%
Net Debt-88.62M $
Net Debt/EBITDA2.27
Balance Sheet
Debt/Equity0.02
Current Ratio9.23
Quick Ratio8.78
Book Value/Sh25.25 USD
Cash/Share33.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:75
Split DateAug 7, 2025
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)147.88 USD
Upside (mean)+186.7%
Target Range104.00 USD – 230.00 USD
$104.00+186.7% to mean$230.00
# Analysts8
Ownership
Shares Out.2.87M
Float2.02M
Insiders3.37%
Institutions76.64%
Short Interest
Short Ratio6.7d
Short % Float15.75%
Short % Out.15.59%
Shares Short429.12K
Short (prev mo.)359.39K
Technical
SMA 5048.52 (+6.3%)
SMA 20066.56 (-22.5%)
Beta3.34
S&P 52W Chg18.16%
Avg Vol (30d)53.93K
Avg Vol (10d)42.92K
Technical Indicators
RSI (14)62.0
MACD1.3206
MACD Signal0.3699
MACD Hist.+0.9508
BB Upper54.74 USD
BB Middle46.76 USD
BB Lower38.78 USD
BB Width34.14%
ATR (14)2.913 USD
Vol Ratio (20d)1.33x